Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Classical hematology 1

Conditions

Small Cell Lung Carcinoma 1Sarcoma 1Fanconi Anemia 1

Interventions

Gemcitabine 5Docetaxel 4tislelizumab 3Bortezomib 3spartalizumab 2pembrolizumab 2Nivolumab 2Irinotecan 2Filgrastim 2Cisplatin 2Capecitabine 2130-nm albumin-bound paclitaxel 2trastuzumab deruxtecan 1tinostamustine 1talazoparib 1surufatinib 1regorafenib 1pazopanib 1pamiparib 1liposomal doxorubicin 1isophosphamide mustard 1futibatinib 1etoposide phosphate 1entinostat 1cc-486 1cabozantinib 1atezolizumab 1anlotinib 1Vinorelbine 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × SRA737 × Sarcoma × Clear all
NCT02797977 2023-06-22

A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects

Sierra Oncology LLC - a GSK company

Phase 1/2 Completed
153 enrolled
Classical hematologySarcomaThoracic

Fanconi Anemia, Sarcoma, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡